KIT and acute myeloid leukemia: Multivariate analysis identified KIT exon 17 mutations as an independent predictor of inferior DFS in patients with RUNX1-RUNXIT1+ AML(P<0.001), and allo-HSCT significantly prolonged DFS in these patients(P=0.010).